June 21, 2022
COVID-19 rebound following Paxlovid treatment likely due to insufficient drug exposure, UC San Diego researchers find after showing rebound patient did not show drug resistance or impaired immunity.
October 31, 2022
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
March 22, 2023
UC San Diego researchers describe why SARS-CoV-2 subvariants spread more rapidly than the original virus strain, and how an early treatment might have made people more susceptible to future infections.
February 24, 2022
…Pfizer that developed the Paxlovid COVID-19 antiviral pill, the first oral antiviral treatment for COVID-19 to receive FDA emergency use authorization. Boras shared what led him to UC San Diego, how his graduate degree prepared him for his career, and what it was like to work on such a timely…
June 3, 2024
UC San Diego pharmacy student Grace Riggs outcompeted over a hundred students from across the country in the National Patient Counseling Competition, sponsored by the American Pharmacists Association (APhA) and the Academy of Student Pharmacists (ASP).
January 23, 2023
Researchers at University of California San Diego and UC Riverside have further elucidated the molecular pathway used by the SARS-CoV-2 virus to infect human lung cells, identifying a key host-cell player that may prove a new and enduring therapeutic target for treating COVID-19.
July 21, 2023
Researchers have created a resource for analyzing how viruses infect human cells. The fruit fly-based toolkit provides a shortcut for assessing SARS-CoV-2 genes and understanding how they interact with human proteins, offering researchers a resource for new COVID-related drug therapies.
December 15, 2022
As we look forward to the upcoming new year, UC San Diego Today invites readers to take a look back at some milestones from 2022.
